Philogen S.p.A. (BIT:PHIL)

Italy flag Italy · Delayed Price · Currency is EUR
22.60
+0.10 (0.44%)
Jul 18, 2025, 5:35 PM CET
8.65%
Market Cap907.47M
Revenue (ttm)77.65M
Net Income (ttm)45.29M
Shares Out40.33M
EPS (ttm)1.12
PE Ratio20.09
Forward PE2.50
Dividendn/a
Ex-Dividend Daten/a
Volume4,431
Average Volume36,970
Open22.50
Previous Close22.50
Day's Range22.50 - 22.80
52-Week Range16.50 - 27.80
Beta0.14
RSI51.96
Earnings DateSep 23, 2025

About Philogen

Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases. The company is developing Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF developed intralesional treatment for locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory product consisting of the human L19 antibody fused to the human cytokine inter... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1996
Employees 183
Stock Exchange Borsa Italiana
Ticker Symbol PHIL
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.